Live Breaking News & Updates on Ian Michael Estepan

Stay updated with breaking news from Ian michael estepan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Moderate Buy" by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month […] ....

United States , Ian Michael Estepan , Bilal Arif , T Bank Corp , Royal Bank , Daiwa Securities Group Inc , Sarepta Therapeutics Inc , Securities Exchange Commission , Jpmorgan Chase Co , Principal Financial Group Inc , Sumitomo Mitsui Trust Holdings Inc , Sarepta Therapeutics , Get Free Report , Michael Estepan , Exchange Commission , Mitsui Trust Holdings , Retirement System , Securities Group , Principal Financial Group , Financial Group , Get Free , Sarepta Therapeutics Daily ,

Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 36.25% from the stock’s previous close. A number […] ....

Ian Michael Estepan , Bilal Arif , Mather Group , Sarepta Therapeutics Company Profile , Montaga Associates Inc , Partners Investment Advisory , Principal Securities Inc , Sarepta Therapeutics Inc , Riggs Asset Managment Co , Securities Exchange Commission , Cantor Fitzgerald , Sarepta Therapeutics , Get Free Report , Exchange Commission , Michael Estepan , Asset Managment , Cary Street Partners Investment Advisory , Street Partners Investment Advisory , Sarepta Therapeutics Daily ,

Sarepta Therapeutics' (SRPT) "Neutral" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $128.00 target price on the biotechnology company’s stock. Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and […] ....

Ian Michael Estepan , Mather Group , Sarepta Therapeutics Inc , Partners Investment Advisory , Riggs Asset Managment Co , Cantor Fitzgerald , Principal Securities Inc , Montaga Associates Inc , Securities Exchange Commission , Sarepta Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Kathryn Jean Boor , Exchange Commission , Michael Estepan , Asset Managment , Cary Street Partners Investment Advisory , Street Partners Investment Advisory , Sarepta Therapeutics Daily , Nasdaq Srpt , Reiterated Rating ,

10,146 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Sapient Capital LLC

Sapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,146 shares of the biotechnology company’s stock, valued at approximately $978,000. Several other institutional investors also recently bought […] ....

New York , United States , Bilal Arif , Ian Michael Estepan , Sapient Capital , Cantor Fitzgerald , Exchange Commission , Securities Exchange Commission , Sarepta Therapeutics Inc , Partners Investment Advisory , York Life Investment Management , Sarepta Therapeutics , Free Report , Capital Wealth Advisors , Street Partners Investment Advisory , New York Life Investment Management , Michael Estepan , Get Free Report , Sarepta Therapeutics Daily , Nasdaq Srpt , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,